Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘Europe’

One of the delights of going to a major medical/scientific meeting such as the recent European Society for Medical Oncology (ESMO) Congress in Barcelona is that there often meetings going on around it, which offer unique and novel perspectives.

For example, on the Thursday before ESMO19 there was a one-day workshop on “Breaking through emergent immunotherapy and immune targets in cancer.”

Dr Manel Juan Otero presenting at the FLS Science symposium

Organized by FLS Science, it took place at the Casa de Convalescència in Barcelona. The program featured a mix of Spanish immunologists and clinicians, along with some leading US researchers including Dr Tom Gajweski (Chicago) and Dr Antoni Ribas (UCLA).

It was definitely well worth attending and I encourage you to look out to see if the organizers run the again meeting before ESMO20 in Madrid next year.

One of the most interesting speakers at the meeting was Dr Manel Juan Otero (right) who heads up the section of immunotherapy at the Hospital Clinic of Barcelona.

In his talk, he spoke about the “Future Directions for CAR-T Therapy” in Spain, which turned out to be a dramatic one with unexpectedly broad European implications.

During a lunch break at the meeting, Dr Juan Otero kindly spoke to BSB about his plans, which could have an impact on commercial CAR T cell therapy companies such as Novartis and Gilead.

To learn more from our coverage on breast cancer and get a heads up on insights from our latest thought leader interview, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

One of the messages that I have taken away from the European Association of Urology meeting in Vienna, is the increasing complexity of treatment options for advanced prostate cancer.  However, I have equally come away with the impression that company sponsored sessions is not the right way to provide continuing medical education (CME), if not done in an independent way.  

There are 28 industry symposia at EAU in Vienna, each sponsored by one company.  That’s a lot! Of the sessions I have been too, all have prominently featured the company logo, name or some form of branding on the invitations, slides and meeting materials.  If you want more information afterwards, the pharma company (not any CME provider), will contact you. 

What’s more the slides presented are all in a similar format no doubt having been prepared by the company’s agency, and the content appears to have been carefully scripted to focus on the company’s product. 

So when sanofi-aventis at their symposia talk about prostate cancer and discuss one patient, it should come as no surprise that the patient ended up on cabazitaxel, and the only clinical trial data presented in any great detail was, you guessed it, for cabazitaxel.  “You can start using it tomorrow in your practice” was the underlying message.

The key opinion leaders (KOLs) at these sponsored meetings focus their messages where they have no doubt been directed. “In my hands cabazitaxel is well tolerated.”   It’s been fun to watch the same KOL turn up at different symposia, and focus his messaging on a different product each time.  A paid advocate for one product does not take his advocacy with him to another company’s symposia!

While I don’t doubt that the information each company presents is technically and factually accurate, it’s clear that the experienced KOLs know not to bite the hand that feeds and play the game. But should doctors have to attend multiple symposia to work out how to put the pieces of the jigsaw together?

The model I have seen at United States medical meetings where a topic is focused on, and sponsoring companies have no role in writing the slides, selecting the KOLs or scripting it, is far superior.  Fair balance and independence for CME activities are what doctors deserve in a promotional world. 

The challenge of quasi-promotional symposia such as the ones I have attended in Vienna, is that doctors can’t rely on the company sponsored session to help them understand how to view competing or different treatment options. As advanced prostate cancer becomes more complex, the need for independent CME becomes increasingly important.  European physicians should insist on nothing less.

Free Email Updates
Subscribe to new post alerts, offers, and additional content!
We respect your privacy and do not sell emails. Unsubscribe at any time.
error: Content is protected !!